The groundbreaking success of the copyright undeniably reshaped the drug landscape, but placing funds in companies primarily reliant on off-patent versions presents a complex picture. Although early earnings were impressive, the cessation of patents and the appearance of less expensive alternatives have diminished sales. Therefore, a thorough evalu